Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
After efficient EGFR-mediated cellular uptake, the ZEGFR:1907-PMI-DX8591 ADCN released DX8591 and PMI intracellularly, leading to synergistic p53 activation by inducing p53 production and blocking its degradation. In EGFR-positive non-small cell lung tumor models, the ADCN showed excellent tumor accumulation and achieved 81.7% tumor growth inhibition, which was 1.5-fold and 1.2-fold higher than those of the ZEGFR:1907-PMI and ZEGFR:1907-DX8591 monotherapies, respectively.
| Market | Status | Year |
|---|---|---|
| United States | Not approved | — |
| European Union | Not approved | — |
| China | Not approved | — |
| Japan | Not approved | — |
Approved indications and other markets are in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ZEGFR:1907-PMI-DX8591.
Work on ZEGFR:1907-PMI-DX8591? Claim this page to correct or add information. Claim this page